Vanderbilt-Ingram Cancer Center

VUMC in the news, Jan. 9, 2024

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.

Appointments, additions in 2023 strengthen VUMC’s core missions

During the past year, multiple new appointments and additions strengthened VUMC’s core missions.

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)

Clinical trial shows efficacy for atezolizumab combined with carboplatin

Sam S. Chang, MD, MBA

Sam S. Chang recognized by the American Urological Association

The American Urological Association has announced that Vanderbilt’s Sam S. Chang, MD, MBA, is one of its 2024 award recipients.

The visit was the first time a group of Ukrainian oncologists came to VUMC to learn about cancer research and care.

Ukrainian oncologists visit Vanderbilt-Ingram Cancer Center

A group of Ukrainian oncologists recently visited Vanderbilt-Ingram Cancer Center where they toured research labs, observed tumor board meetings, met with several Vanderbilt oncologists, and attended the 23rd Annual Retreat for Cancer Biology.

1 6 7 8 9 10 28